Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1999 Jul;9(3):469-79.
doi: 10.1111/j.1750-3639.1999.tb00536.x.

Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines

N Ishii  1 , D Maier, A Merlo, M Tada, Y Sawamura, A C Diserens, E G Van Meir
Affiliations

Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines

N Ishii et al. Brain Pathol. 1999 Jul.

Abstract

In this study we established the simultaneous status of TP53, p16, p14ARF and PTEN tumor suppressor genes in 34 randomly chosen human glioma cell lines. Nine cell lines (26.4%) harbored mutations or deletions in all four tumor suppressor genes and 22 cell lines (64%) had alterations in at least three. Mutations/deletions were found at the following frequencies: TP53 (76.5%), p14ARF (64.7%), p16 (64.7%), PTEN (73.5%). Thus, there was a high incidence of alterations in the cellular pathways involving the p53 transcription factor (94.1%), the retinoblastoma protein (64.7%) and the PTEN phosphatase (73.5%) and 91% of cell lines carried mutations in two or more pathways. This provides the first clear genetic evidence that these tumor suppressors participate in biological pathways which are functioning separately/independently in glioma cells. The status of the gene alterations did not correlate with tumorigenicity in immunocompromized mice or any clinical parameters. Although the mutation rate was higher in glioma cell lines than that reported for glioma tissues, the alterations were molecularly representative of those found in adult de novo glioblastoma. This study highlights the importance of developing therapeutic approaches applicable to tumors with a broad range of genetic alterations and also provides an invaluable panel of glioma cell lines to make this possible.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Albertoni M, Daub MD, Arden KC, Viars C, Powell C, Van Meir EG (1998). Genetic instability leads to loss of both p53 alleles in a human glioblastoma. Oncogene. 16: 321–6. - PubMed
    1. Anker L, Ohgaki H, Ludeke BI, Herrmann HD, Kleihues P, Westphal M (1993). p53 protein accumulation and gene mutations in human glioma cell lines. Int J Cancer. 55: 982–7. - PubMed
    1. Arap W, Nishikawa R, Furnari FB, Cavenee WK, Huang HJ (1995). Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res. 55: 1351–4. - PubMed
    1. Bigner SH, Humphrey PA, Wong AJ, Vogelstein B, Mark J, Friedman HS, Bigner DD (1990). Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res. 50: 8017–22. - PubMed
    1. Bigner SH, Mark J, Burger PC, Mahaley MJ, Bullard DE, Muhlbaier LH, Bigner DD (1988). Specific chromosomal abnormalities in malignant human gliomas. Cancer Res. 48: 405–11. - PubMed

Publication types

MeSH terms